CCL8 and cancer: Notably, supernatants from TSN-exposed healthy donor–derived CD14+ cells (conditioned medium from TSN-exposed monocytes [TCM]) could also markedly increase the migration of HepG2 cells in comparison with those from untreated normal monocytes (conditioned medium from control [untreated] monocytes [CCM]), and this increase could be effectively attenuated by treating TCM-exposed cancer cells with anti-CCL8 antibody (Figure 6, E and F).